Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Bedaquiline, delamanid both effective against multidrug-resistant tuberculosis

23 Apr 2020

The new drugs bedaquiline and delamanid appear to be safe and effective in patients with tuberculosis resistant to multiple treatments, according to the results of a study conducted in South Korea.

Researchers looked at 318 patients, among whom 282 (88.7 percent) were treated with the two drugs (bedaquiline, n=107; delamanid, n=108; both concurrently or sequentially, n=67). They evaluated culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavourable outcomes.

The mean age of the population was 49.3 years, and 197 patients (69.9 percent) were male. Three patients were HIV seropositive, and 151 (53.5 percent) were resistant to quinolone.

The culture conversion rates were 57.4 percent (81/141) at 2 months and 89.4 percent (126/141) at 6 months. The 12-month outcome was favourable in the majority of the population (239/282; 84.8 percent).

Differences in the culture conversion rate or in interim treatment outcomes were not statistically significant according to drug susceptibility test patterns or new drugs used. Further analysis revealed that older age (>60 years) and lower body mass index (<18.5 kg/m2) were significantly associated with unfavourable outcomes at 12 months.

Adverse drug reactions rarely occurred on either bedaquiline or delamanid.

The present data show satisfactory interim treatment results in patients with multidrug-resistant tuberculosis, with no significant differences between the two drugs, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.